Kintor Pharmaceutical
Kintor Pharmaceuticals has announced that its proteolysis targeting chimera (PROTAC) drug GT20029 has reached its primary endpoint in its Phase 2 trial in China. GT20029 is a topical PROTAC targeted toward AGA. What are PROTACs? PROTACs are a novel class of heterobifunctional molecules that can induce the degradation of target proteins by hijacking the cell’s…
Read MoreOn May 11, 2023, Kintor Pharmaceutical of China announced results from their US phase 2 trial testing KX-826 aka pyrilutamide in males with androgenetic alopecia. Successful Phase 2 Trial For US KX-826 Trial As is the trend for Kintor Pharmaceutical’s AGA programs, today’s announcement included positive results in a human trial. This milestone will help…
Read MoreThe long awaited phase II results from Kintor’s KX-826 (pyrilutamide) study in males with androgenetic alopecia have surfaced online. KX-826 Phase 2 Results Presentation Several months ago in May, the 28th Annual Meeting of the Chinese Society of Dermatology was postponed from June to the beginning of September 2022. This was the acclaimed conference where…
Read More